In a retrospective study, Dr Muller and colleagues have assessed the efficacy of mupirocin nasal ointment alongside hygienic measures in methicillin-resistant Staphylococcus aureus (MRSA)-positive patients admitted to the intensive care unit (ICU). Their findings, which suggest that intranasal mupirocin can prevent ICU-related MRSA infections, need confirmation in a well-designed clinical trial. In general: early identification, isolation and treatment of all MRSA carriers, including health care workers, and disinfection of contaminated environments, are the main 'ingredients' of an effective MRSA 'search and destroy' program.

Additional Metadata
Keywords *Methicillin Resistance, Administration, Intranasal, Anti-Bacterial Agents/administration & dosage/*therapeutic use, Cross Infection/*prevention & control, Humans, Intensive Care Units, Mupirocin/administration & dosage/*therapeutic use, Staphylococcal Infections/*prevention & control
Persistent URL dx.doi.org/10.1186/cc3720, hdl.handle.net/1765/17743
Citation
Wertheim, H.F.L., & Vos, M.C.. (2005). Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?. Critical Care (Print), 9(3), 257–258. doi:10.1186/cc3720